Should We Start Using Ultra-Thin Struts?

The benefits of DES are well known, as well as the benefits of more recent polymer-based DES versions (even those with no polymers). However, strut size is no small matter, and might even make the difference, seeing as thinner struts are associated to better deliverability, simpler crossing profile in bifurcations, better endothelization and healing. Besides, it reduces vessel injury, inflammation, neointimal proliferation and thrombogenesis. 

struts ultrafinos

Even though the latter has already been established, the long-term benefits of ultra-thin struts have not yet been looked at. 

The BIOFLOW V randomized 1334 patients. 884 (66.2%) received ultra-thin bioresorbable polymer sirolimus eluting stent ORSIRO (BP SES) and 450 patients received XIENCE durable polymer everolimus eluting stent (DP EES).

Primary end point was target lesion failure (TLF) defined as the composite of cardiac death, target vessel MI (TV MI) or ischemia driven target lesion revascularization (TLR).

The groups were similar. Neither were there differences in lesion length, vessel diameter or lesion characteristics.

Primary end point at 5 year was similar between the groups (12.3% BP SES and 15.3% for DP EES P=0.108).

Read also: Calcified Lesions: CTO Strategies for Plaque Preparation.

Patients receiving BP SES presented less TV MI (6.6% vs 10.3%, P= 0.015) and lesS ischemia driven TLR, though with no statistical significance (5.9% vs 7.7% P=0.2). The incidence of death was 2.6% vs. 1.9% (P=0.49).

The presence of late/ very late/ definite and probable thrombosis was 0.3% in the BP SES group and 1.6% in the DP ESS (P=0.02).

Conclusion

In this large, randomized study, TLF, death and TLR at 5 years were similar between those receiving BP SES vs DP EES. Target vessel failure and late/very late/definite and probable thrombosis was significantly lower with BP SES. These results confirmed durability and safety and efficacy of PCI with ultra-thin bioresorbable polymer sirolimus eluting stents.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents BIOFLOW V Final 5-Year Outcomes

Reference: David E. Kandzari, et al. J Am Coll Cardiol Intv 2022;15:1852–1860.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...